A Comparison of an Australian Observational Longitudinal Alzheimer's Disease Cohort to Community-Based Australian Data

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2024 Aug 30

PMID 39213065

Authors

Andrew Liem Hieu Huynh

Yihan Wang

Liwei Ma

Yi Ling Clare Low

Weisi Chen

Christopher Fowler

Edwin C K Tan

Colin L Masters

Liang Jin

Yijun Pan

Affiliations

Soon will be listed here.

Abstract

Background: Observational Alzheimer's disease (AD) cohorts including the Australian, Biomarkers, Imaging and Lifestyle (AIBL) Study have enhanced our understanding of AD. The generalizability of findings from AIBL to the general population has yet to be studied.

Objective: We aimed to compare characteristics of people with AD dementia in AIBL to 1) the general population of older Australians using pharmacological treatment for AD dementia, and to 2) the general population of older Australians who self-reported a diagnosis of dementia.

Methods: Descriptive study comparing people aged 65 years of over (1) in AIBL that had a diagnosis of AD dementia, (2) dispensed with pharmacological treatment for AD in Australia in 2021 linked to the Australian census in 2021 (refer to as PBS/census), (3) self-reported a diagnosis of dementia in the 2021 Australian census (refer to as dementia/census). Baseline characteristics included age, sex, highest education attainment, primary language, and medical co-morbidities.

Results: Participants in AIBL were younger, had more years of education, and had a lower culturally and linguistically diverse (CALD) population compared to the PBS/census cohort and dementia/census cohort (mean age±standard deviation - AIBL 79±7 years, PBS/census 81±7, p < 0.001, dementia/census 83±8, p < 0.001; greater than 12 years of education AIBL 40%, PBS/census 35%, p = 0.020, dementia/census 29%, p < 0.001; CALD - AIBL 3%, PBS/census 20%, p < 0.001, dementia/census 22%, p < 0.001).

Conclusions: Our findings suggest that care should be taken regarding the generalizability of AIBL in CALD populations and the interpretation of results on the natural history of AD.

Citing Articles

Development and validation of the Florey Dementia Risk Score web-based tool to screen for Alzheimer's disease in primary care.

Pan Y, Chu C, Wang Y, Wang Y, Ji G, Masters C EClinicalMedicine. 2024; 76:102834.

PMID: 39328810 PMC: 11426130. DOI: 10.1016/j.eclinm.2024.102834.

References

Guillemin M, Gillam L, Barnard E, Stewart P, Walker H, Rosenthal D . "We're checking them out": Indigenous and non-Indigenous research participants' accounts of deciding to be involved in research. Int J Equity Health. 2016; 15:8. PMC: 4715344. DOI: 10.1186/s12939-016-0301-4. View

Gianattasio K, Bennett E, Wei J, Mehrotra M, Mosley T, Gottesman R . Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC. Alzheimers Dement. 2021; 17(8):1265-1276. PMC: 8359773. DOI: 10.1002/alz.12293. View

Low L, Barcenilla-Wong A, Brijnath B . Including ethnic and cultural diversity in dementia research. Med J Aust. 2019; 211(8):345-346.e1. DOI: 10.5694/mja2.50353. View

Dubois B, Feldman H, Jacova C, Hampel H, Molinuevo J, Blennow K . Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014; 13(6):614-29. DOI: 10.1016/S1474-4422(14)70090-0. View

Lang L, Clifford A, Wei L, Zhang D, Leung D, Augustine G . Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open. 2017; 7(2):e011146. PMC: 5293981. DOI: 10.1136/bmjopen-2016-011146. View

Radford K, Mack H, Draper B, Chalkley S, Daylight G, Cumming R . Prevalence of dementia in urban and regional Aboriginal Australians. Alzheimers Dement. 2014; 11(3):271-9. DOI: 10.1016/j.jalz.2014.03.007. View

Lavrencic L, Delbaere K, Broe G, Daylight G, Draper B, Cumming R . Dementia Incidence, Genotype, and Risk Factors for Cognitive Decline in Aboriginal Australians: A Longitudinal Cohort Study. Neurology. 2022; 98(11):e1124-e1136. DOI: 10.1212/WNL.0000000000013295. View

George S, Duran N, Norris K . A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders. Am J Public Health. 2013; 104(2):e16-31. PMC: 3935672. DOI: 10.2105/AJPH.2013.301706. View

Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A . Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7(3):280-92. PMC: 3220946. DOI: 10.1016/j.jalz.2011.03.003. View

10.

Zilkens R, Duke J, Horner B, Semmens J, Bruce D . Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010. Alzheimers Dement. 2013; 10(3):310-8. DOI: 10.1016/j.jalz.2013.04.001. View

11.

Welberry H, Brodaty H, Hsu B, Barbieri S, Jorm L . Measuring dementia incidence within a cohort of 267,153 older Australians using routinely collected linked administrative data. Sci Rep. 2020; 10(1):8781. PMC: 7260191. DOI: 10.1038/s41598-020-65273-w. View

12.

Villemagne V, Burnham S, Bourgeat P, Brown B, Ellis K, Salvado O . Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013; 12(4):357-67. DOI: 10.1016/S1474-4422(13)70044-9. View

13.

Lin X, Wallis K, Ward S, Brodaty H, Sachdev P, Naismith S . The protocol of a clinical quality registry for dementia and mild cognitive impairment (MCI): the Australian dementia network (ADNeT) Registry. BMC Geriatr. 2020; 20(1):330. PMC: 7487842. DOI: 10.1186/s12877-020-01741-2. View

14.

Ashford M, Raman R, Miller G, Donohue M, Okonkwo O, Rivera Mindt M . Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2022; 18(12):2603-2613. PMC: 9402812. DOI: 10.1002/alz.12640. View

15.

Smith K, Flicker L, Lautenschlager N, Almeida O, Atkinson D, Dwyer A . High prevalence of dementia and cognitive impairment in Indigenous Australians. Neurology. 2008; 71(19):1470-3. DOI: 10.1212/01.wnl.0000320508.11013.4f. View

16.

Lupton M, Robinson G, Adam R, Rose S, Byrne G, Salvado O . A prospective cohort study of prodromal Alzheimer's disease: Prospective Imaging Study of Ageing: Genes, Brain and Behaviour (PISA). Neuroimage Clin. 2020; 29:102527. PMC: 7750170. DOI: 10.1016/j.nicl.2020.102527. View

17.

Fowler C, Rainey-Smith S, Bird S, Bomke J, Bourgeat P, Brown B . Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. J Alzheimers Dis Rep. 2021; 5(1):443-468. PMC: 8293663. DOI: 10.3233/ADR-210005. View

18.

Brijnath B, Croy S, Sabates J, Thodis A, Ellis S, de Crespigny F . Including ethnic minorities in dementia research: Recommendations from a scoping review. Alzheimers Dement (N Y). 2022; 8(1):e12222. PMC: 9053375. DOI: 10.1002/trc2.12222. View

19.

Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S . Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248):413-446. PMC: 7392084. DOI: 10.1016/S0140-6736(20)30367-6. View

20.

Brayne C, Moffitt T . The limitations of large-scale volunteer databases to address inequalities and global challenges in health and aging. Nat Aging. 2023; 2(9):775-783. PMC: 10154032. DOI: 10.1038/s43587-022-00277-x. View